Voquezna Triple, Dual Pak Approved for H. Pylori Infection Treatment
The approval was based on data from a phase 3 study that compared Voquezna Triple and Dual Pak with lansoprazole plus amoxicillin and clarithromycin.
The approval was based on data from a phase 3 study that compared Voquezna Triple and Dual Pak with lansoprazole plus amoxicillin and clarithromycin.
The US Department of HHS added 8 new substances to the 15th Report on Carcinogens, bringing the total list to 256 substances.
The applications are based on data from the phase 3 PHALCON-HP trial.
Vonoprazan is an oral small molecule potassium-competitive acid blocker.
A team of investigators conducted a prospective, multicenter study to assess the safety of H pylori eradication therapy in adolescent students.